
Sana Biotechnology (SANA) Stock Forecast & Price Target
Sana Biotechnology (SANA) Analyst Ratings
Bulls say
Sana Biotechnology has demonstrated a positive outlook based on significant advancements in its proprietary cell engineering programs, with increased probabilities of success for various platforms, notably the T1D and AID platforms, reflecting strong therapeutic potential. The favorable safety profile and sustained efficacy of its UP421 program, alongside promising data from mouse studies, bolsters confidence in the company’s HIP-technology's long-term viability and effectiveness. Overall, these developments, combined with updated financial models indicating increased probabilities of success for several product candidates, underpin a robust foundation for Sana Biotechnology's future growth prospects.
Bears say
Sana Biotechnology Inc. faces a significant financial outlook marked by anticipated substantial operating losses for the foreseeable future, indicating potential challenges in achieving profitability. The company's research and development expenses are higher than estimated, coupled with a projected need for approximately $1.1 billion to $1.4 billion in additional financing through 2040 to maintain operations. Furthermore, various risks, including safety concerns in clinical programs, regulatory challenges, and intense market competition, could exacerbate the negative impact on the company's stock performance, regardless of operational achievements.
This aggregate rating is based on analysts' research of Sana Biotechnology and is not a guaranteed prediction by Public.com or investment advice.
Sana Biotechnology (SANA) Analyst Forecast & Price Prediction
Start investing in Sana Biotechnology (SANA)
Order type
Buy in
Order amount
Est. shares
0 shares